EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions

Karin Hellner iD, Philippe Simon, Philippe De Sutter, Kadri-Liina Vahula, Paula Briggs, Ülle Kiisla, Michelle Russell, Claire Newton, Kobe Dewilde iD, Katie Anderson, Jakub Kopycinski, Antonella Vardeu und 11 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf658 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Karin Hellner und 22 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Women's and Reproductive Health, Oxford University, Oxford, United Kingdom. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus Vaccines, Adenoviruses, Simian, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Barinthus Biotherapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The clearance of high-risk oncogenic human papillomaviruses (hrHPV) and related cervical lesions is associated with the development of a robust T-cell response. Therapeutic vaccination that induces HPV antigen-specific T cells is a promising approach.

Method

A 2-vector dosing strategy using Chimpanzee Adenovirus Oxford 1-HPV and Modified Vaccinia virus Ankara-HPV, both encoding the same multiantigen HPV cassette was given on a 0/28-day schedule to participants with persistent cervical hrHPV and a history of low-grade cervical lesions. An open-label lead-in was followed by a randomized, blinded, placebo-controlled main phase. The primary endpoint was the safety of the different dose regimens; secondary endpoints included immunogenicity, and clearance of hrHPV and associated lesions at 12 months. Nine participants were enrolled in the lead-in and 99 were randomized 67:32 to 5 active dose arms or placebo, respectively.

Results

The regimens were well-tolerated with no grade 3–related treatment emergent adverse events or serious adverse reactions. All dosing regimens generated antigen-specific CD4+ and CD8+ T-cell responses. There was no difference in hrHPV clearance between the pooled active groups and placebo (20/64 [31.3%] versus 10/30 [33.3%]; P > .99), nor in lesion clearance. A trend toward higher hrHPV clearance (60%) was observed with the highest Chimpanzee Adenovirus Oxford 1-HPV doses. No association between the peripheral immune response and clearance was demonstrated.

Conclusions

A heterologous, multiantigenic HPV 2-component immunotherapy regimen was well-tolerated and immunogenic but did not result in a statistically significant clearance of either hrHPV or the associated cervical lesions in women with persistent high-risk HPV infections.

Trial registration

EudraCT 2019-001890-98; NCT04607850

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsPapillomavirus VaccinesAdenoviruses, SimianUterine Cervical NeoplasmsHuman Papillomavirus VirusesFemaleHumansAdultVaccinia virusAnimalsYoung AdultGenetic VectorsMiddle AgedAdolescentTreatment Outcome

Stichwörter der Autor:innen

ChAdOx1HPVMVAimmunotherapeutic

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Nuffield Department of Women's and Reproductive Health, Oxford University, Oxford, United Kingdom.
  • Department of Gynaecology, HUB Hospital Erasme, Bruxelles, Belgium.
  • Department of Gynaecology, UZ Brussels, Jette, Belgium.
  • Pärnu Hospital Women's and Children's Clinic, Pärnu, Estonia.
  • Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom.
  • North Estonia Medical Centre Foundation Surgery Clinic, Tallinn, Estonia.

ORCID-Profile: Karin Hellner, Kobe Dewilde, Vicky Wheeler, Matthew Downs, Gemma Hancock, Kate Cuschieri

Förderung

  • Barinthus Biotherapeutics

Zitieren

APA

Hellner, K., Simon, P., De Sutter, P., Vahula, K. L., Briggs, P., Kiisla, Ü., Russell, M., Newton, C., Dewilde, K., Anderson, K., Kopycinski, J., Vardeu, A., Davis, C., Sebastian, S., Kennerley, R., Wheeler, V., Jones, B., Tait, D., Downs, M., …, & Evans, T. (2026). A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf658

Vancouver

Hellner K, Simon P, De Sutter P, Vahula KL, Briggs P, Kiisla Ü, et al. A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf658

BibTeX
@article{Hellner2026,
  author = {Hellner, Karin and Simon, Philippe and De Sutter, Philippe and Vahula, Kadri-Liina and Briggs, Paula and Kiisla, Ülle and Russell, Michelle and Newton, Claire and Dewilde, Kobe and Anderson, Katie and Kopycinski, Jakub and Vardeu, Antonella and Davis, Charlotte and Sebastian, Sarah and Kennerley, Raisha and Wheeler, Vicky and Jones, Bethan and Tait, Dereck and Downs, Matthew and Dorrell, Lucy and Hancock, Gemma and Cuschieri, Kate and Evans, Thomas},
  title = {A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf658}
}
Kostenlos starten →